Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -8 of 8 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/11/2008 First Published: 6/1/1999


1.		Phase III Randomized Study of High-Dose Aldesleukin With or Without gp100 Antigen in Patients With Locally Advanced or Metastatic Cutaneous Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				CCCGHS-NCI-T98-0085 NCI-T98-0085, NCI-99-C-0051B, T98-0085, NCT00019682

Last Modified: 10/31/2008 First Published: 11/1/1999


2.		Phase II Study of Adoptive Transfer of Cloned Lymphocytes With Interleukin-2 After Cyclophosphamide and Fludarabine in Patients With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				16 and over				NCI				NCI-99-C-0158 NCI-T99-0078, T99-0078, NCT00019942

Last Modified: 11/16/2008 First Published: 5/28/2004


3.		Phase II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) and Peptide Vaccine Comprising Tyrosinase, gp100 Antigen, and MART-1 Antigen Emulsified in Montanide ISA-51 in Patients With Resected Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				MCC-15241 MDX-010-16, NCI-6446, 6446, NCT00084656, LAC-USC-10M036

Last Modified: 11/16/2008 First Published: 5/28/2004


4.		Phase II Randomized Study of Immunization With Autologous Dendritic Cells (DC) Pulsed With gp100 Antigen Versus Autologous DC Fused With Autologous Tumor Cells in Patients With Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Any age				NCI				DFCI-03123 NCT00085397


5.		Melanoma Vaccine With Peptides and Leuprolide

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				2004-0502 NCT00254397

Last Modified: 11/17/2008 First Published: 3/13/2006


6.		Phase II Randomized Study of Adjuvant gp100 Peptide Immunization With or Without Montanide ISA 51 and/or Imiquimod in Patients With Resected High-Risk Melanoma (Treatment Arms I-IV Closed to Accrual as of 1/11/08)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				16 and over				NCI				NCI-06-C-0069 7676, NCI-7676, NCI-P6703, NCT00304057

Last Modified: 11/18/2008 First Published: 8/24/2004


7.		Phase I Randomized Pilot Study of Fludarabine Followed By Vaccination Comprising Modified gp100 Peptide, Montanide ISA-51, and Keyhole Limpet Hemocyanin Combined With Autologous Peripheral Blood Mononuclear Cell Reinfusion in Patients With Unresectable or Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				PPMC-IRB-02-99 NCI-6361, 6361, NCT00091143


8.		Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				Over 18				Other				Pro00000806 IND # BB-13545, NIH OBA # 0708-874, NCT00672542

Select All on One Page